Sarcomas are a group of heterogeneous mesodermal malignancies that encompass a diverse range of diVerent histological subtypes [1] . For early stage sarcoma surgical resection remains the mainstay of treatment. However, in the metastatic setting, systemic treatment with chemotherapy is the main treatment option for many sarcoma subtypes. Doxorubicin and ifosfamide have shown reproducible activity in treating sarcomas [2] . Recently, trabectedin, a natural marine-derived product, has emerged as an active agent, particularly in some subtypes such as myxoid/round cell liposarcoma, refractory to anthracyclines and ifosfamide [3, 4] . In addition, other histological subtypes could be oVered other systemic therapy regimens, such as gemcitabine and docetaxel in leiomyosarcoma and pegylated liposomal doxorubicin in angiosarcoma [2, 5] .
The utility of imatinib [6] and sunitinib [7] in gastro intestinal stromal tumours (GIST) has highlighted the potential for novel targeted agents to revolutionise the treatment of a rare disease previously assigned as resistant to systemic therapy [2] . Other emerging molecularly targeted drugs have shown promising results in early trials, such as IGF1-R (Insulin-like Growth Factor-1 Receptor) monoclonal antibodies in Ewing's sarcoma [8, 9] . However, there still remains a pressing need for new therapeutic approaches in other sarcoma subtypes.
Phase I oncology clinical trails are dose-Wnding and toxicity-deWning studies, primarily designed to establish a safe dose and schedule for further evaluation in Phase II trials, although sometimes Phase I trials can also have pharmacokinetic or pharmacodynamic objectives as primary aims. Furthermore, antitumour activity derived from these trials is never considered the primary endpoint, but both patients and clinicians actively seek clinical activity.
Currently, there is little published data on the clinical beneWt and risk derived by sarcoma patients treated within Phase I trials [10] , although recent reports involving pooled analysis of Phase I patients suggest objective response rates between (7.2-9.4%) and a clinical beneWt rate at 3 months of (48.2-53%).
At our Institution, patients (of adequate performance status) with advanced sarcoma who have no standard treatment options have traditionally been oVered the possibility of participation in a Phase I clinical trial. We are unaware of any other study analysing the outcome and potential prognostic factors in sarcoma patients treated within Phase I clinical trials.
Patients and methods
This study included all consecutive sarcoma patients treated prospectively within Phase I trials in the Sarcoma and Drug Development Units at the Royal Marsden Hospital (RMH), from 1st August 1998 and 31st December 2009. From the hospital records, we selected only patients who met the following criteria: (1) histological conWrmation by an experienced sarcoma pathologist; (2) Wrst Phase I inclusion; (3) received at least 1 dose of the experimental agent. Several clinical parameters were collected at study entry, including sarcoma subtype, age, sex, Eastern Cooperative Oncology Group (ECOG) performance status (PS), full blood count, biochemistry (lactate dehydrogenase and albumin), number of metastatic sites, and prior oncology treatment, including the number of prior systemic therapies. Using these data, we derived the validated RMH prognostic score [11, 12] . All patients included in this analysis gave written informed consent for participation in a Phase I trial, and approval from the Royal Marsden Audit Committee was obtained prior to commencing this study.
Patient follow-up and response evaluation From 2003 onwards, baseline tumour measurements were performed within 4 weeks of the Wrst administration of study drug; between 1998 and 2002, patients had baseline measurements performed up to 8 weeks prior to Wrst administration of study drug. Tumour measurements were repeated every 6-8 weeks during the Wrst 6 months on trial. Tumour responses were conWrmed retrospectively by a radiologist using Response Evaluation Criteria In Solid Tumours (RECIST) [13] . Toxicity and maximum grade were collected as originally recorded in the medical records, and when required, the clinical trial record. In all trials included in the present analysis, toxicity was graded according to the Common Terminology Criteria for Adverse Events (CTCAE), either version 2.0 or 3.0. Survival was obtained form the hospital medical records, and when necessary by contacting the general practitioner or referring institution.
Statistical methods
Overall survival (OS) was deWned as the time between day 1 on Phase I trial and either the date of death or the last follow-up (if death was not observed during the follow-up period). For those patients with evaluable disease for response, progression-free survival time was deWned by the time elapsed between day 1 on treatment until radiological progression or disease-related death (which ever occurred Wrst), if no evidence of progression was documented at last follow-up, PFS was censored at the time of last radiological evaluation. Analysis of the eVect of potential prognostic factors was undertaken using Cox's regression to determine the subset of baseline characteristics that provided independent prognostic information as continuous variables in our series. Subsequently, prior prognostic variables in the RMH score were categorised: elevated LDH (>ULN); low albumin (<35 g/L); and more than two sites of metastatic disease. Other numeric variables were categorised based on their deviation from standard reference. Median PFS and OS as well as their 95% conWdence intervals were determined with the Kaplan-Meier method, and survival curves were compared with the logrank test. We calculated the RMH score based on each weighed equally: LDH normal (0) versus LDH > ULN (+1); albumin more than 35 g/L (0) versus albumin less than 35 g/L (+1); metastatic sites <2 (0) versus more than 2 (+1, see Table 1 ). The prognostic score for each individual was derived from the sum of these three components used in the prognostic model. All P values were 2 sided, and a signiWcance level threshold of 0.05 was used. The analysis was performed using SPSS 15.0 (SPSS Inc., Chicago, Il).
Pathological tumour grade was included in the prognostic analysis, even though grading is not recommended for certain histological subtypes, such as GIST and extraskeletal chondrosarcoma, and for others such as malignant peripheral nerve sheath tumour, it is not regarded as of prognostic value [14, 15] .
Results

Patient characteristics
One hundred and thirty-three sarcoma patients were treated within the Royal Marsden Sarcoma and Drug Development Units between 1st August 1998 and 31st December 2009. The clinical characteristics of these patients are summarised in Table 1 as well as the trial treatment administered. The median age of these patients was 48.0 years (12.5-81.9). There were 71 men and 62 women. The most common histological subtype was leiomyosarcoma (n = 16, 12.0%), followed by GIST and liposarcoma (n = 15, 11.3% each). One hundred and twelve (84.2%) had undergone previous surgery, and 66 (49.6%) had received prior radiotherapy. This series of patients had received a median of 3 (range 0-6) prior lines of systemic therapy, and 7 (5.3%) received treatment with in the Phase I Unit as their Wrst-line systemic therapy. Thirty seven (27.8%) patients had a PS of 0, and 7 (5.3%) had a PS of 2. Twenty Wve (18.8%) patients had a RMH score of 3. The most frequently employed trial drugs were antiangiogenic agents (n = 43, 32.3%) followed by agents targeting the IGF1-R/PI3 K/mTOR/AKT pathway (n = 30, 22.6%).
Tumour response and tolerability
One hundred and twenty-seven patients were evaluable for response according to RECIST, and the other 6 were GIST patients who entered a trial of SR4554, an oxidoreductive agent and hypoxia marker, and were not evaluated for response and progression-free survival. One (0.8%) patient achieved a complete and 2 (1.6%) a partial response to treatment. These responses were observed in two patients with Ewing's sarcoma treated with IGF1-R inhibitors and a patient with alveolar soft part sarcoma treated with an antiangiogenic agent. Stable disease was recorded as the best response in 56 (44.1%) patients. Sixty-eight (53.5%) progressed on therapy at the Wrst radiological evaluation. The median PFS was 2.1 months (95% CI; 1.7-2.5), and the median time to progression was 1.9 months (95% CI; 1.6-2.2). Kaplan-Meier curves of factors with a signiWcant association with progression-free survival are shown in Fig. 1 . The non-progression rate at 3 and 6 months was 31.5% (95% CI 23.4-39.6%) and 11.0% (95% CI 5.6-16.5%), respectively. Twenty-four (18.0%) patients experienced grade 3 or 4 toxicity, and 16 (12.0%) stopped trial treatment due to toxicity. One hundred and four patients (78.2%) only received one Phase I trial, and 29 (21.8%) received further Phase I trials (ranging from 1 to 5 further Phase I trials). Thirtyfour patients (25.6%) also received further systemic therapy following treatment within the Phase I Unit. Two of these patients were treated with both Phase I trials and non-Phase I agents. There were no treatment-related deaths.
Overall survival
The median overall survival was 7.6 months (95% CI 4.8-10.4), see Fig. 1b . The 6-and 12-month OS rates were 55.4% (95% CI; 46.8-64.0%) and 36.3% (95% CI; 27.9-44.7), respectively. The 90-day mortality rate was 16% (95% CI; 9.8-22.2).
Prognostic variables for OS are displayed in Table 2 . Multivariate (MVA) analysis conWrmed the independent prognostic value of serum albumin level (HR 0.89, CI 95% 0.85-0.92, P = 0.0001) and LDH (HR 1.72, CI 95% 1.35-2.20, P = 0.0001). PS and number of metastatic sites were both signiWcant prognostic factors on univariate analysis, but failed to be signiWcant independent factors on multivariate analysis.
The Kaplan-Meier analysis was used to further explore the prognostic value of these factors in our series, in which (1) patients with a low albumin (<35 g/dL) had a shorter OS compared to those with normal albumin (4.0 vs. 12.2 months, P = 0.000002); (2) patients with elevated LDH (>1*ULN) had a poor OS compared to those with normal LDH (4.3 vs. 11.6 months, P = 0.001); (3) patients with ¸3 metastatic sites have a shorter OS than those with less metastatic sites of disease (4.2 vs. 9.8 months, P = 0.007); and These three factors (albumin, LDH and number of metastatic sites) have been prospectively validated in the Phase I RMH score [12] . This score applied to our series identiWed patient groups with improved outcome: RMH score 0-1 (good prognosis) median OS 11.7 months (CI 95% 9.0-14.4) compared to those with worse RMH score (2-3), who had a median OS of 4.2 months (CI 95%3.3-5.1), P = 0.003. A Kaplan-Meier curve of overall survival according to Royal Marsden Score is shown in Fig. 2 . Finally, we used a receiver operator curve (ROC) to estimate the ability of these three prognostic factors to predict the 90-day mortality in our series. The derived RCO curve had an area under the curve of 78% (CI 95% 67.5-88.5, P = 0.00005).
Discussion
Our study suggests that sarcoma patients with advanced disease resistant to conventional chemotherapy can derive clinical beneWt from participation in Phase I trials. This is apparent despite the number of diVerent experimental agents administered as well as the heterogeneous histological subtypes included in our study. We did not perform subgroup analysis according to histological subtype, as the number of patients in each subtype was too small to provide meaningful results. By deWnition, our series of patients were heavily pretreated, having received a median of 3 prior lines of systemic treatment in addition to surgery, radiotherapy or radiofrequency ablation. Furthermore, a previous analysis of all soft tissue sarcoma patients treated at the Royal Marsden Hospital between 1991 and 2005 demonstrated a median overall survival of 12 months following Wrst-line chemotherapy [16] and 8 months following second-line chemotherapy [17] for metastatic/recurrent disease. The median overall survival of 7.6 months of our heterogeneous cohort of patients treated within the Phase I Unit compares favourably with these previous results. Currently, only an abstract presentation at the European Society of Medical Oncology Meeting in 2008 has reported the outcome of sarcoma patients treated within Phase I trials. This study consisted of a very small series (38 patients) and reported a median PFS of 2.7 months and a median OS of 9.2 months [10] . This study also reported a statistically signiWcant diVerence in PFS (but not in OS) between patients treated with antiangiogenic agents and those treated with other agents. We did not observe a signiWcant diVerence in PFS between antiangiogenic agents and those treated with drugs targeting the IGF1-R/PI3K/mTOR/AKT pathway and other Phase I drugs.
Although the objective response rate was low (n = 3, 2.3%) in our study, the non-progression rate of 31.5% at 3 months is encouraging in the context of dose-Wnding experimental trials. A retrospective analysis of 12 clinical trials performed by the European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group suggested a 3-month progression-free rate of ¸40% would be indicative of drug activity in the second-line setting and that a 3-month progression-free rate of ·20% would be indicative of drug inactivity [18] . Furthermore, patients with histological subtypes that are known to be chemo resistant (such as clear cell sarcoma [19] ), could be oVered Phase I entry early in the managementof metastatic disease.
The patients in this study tolerated treatment well, and only 16 (12.0%) stopped therapy due to toxicity. It was not possible to retrospectively ascertain the features of the grade 3/4 toxicity observed, i.e. whether this was due more to the characteristics of the individual patients or the Phase I drugs administered. It is also important to note that there were no treatment-related deaths. In addition, 28 (21.1%) received more than one Phase I trials. Thirty four (25.6%) patients were treated with systemic therapy (not Phase I trial) following participation in a Phase I trial.
We also found serum albumin and LDH to be independent prognostic factors for OS. Our study suggests that the RMH score could be of value in advising sarcoma patients of the potential value of Phase I trial entry.
In conclusion, our retrospective study showed that an unselected series of sarcoma patients derived clinical beneWt from participation in Phase I trials, supporting the active recruitment of sarcoma patients into such trials, particularly if there is molecularly driven hypothesis for drug action. Such beneWt is likely to increase with greater understanding of the biology of this complex group of diseases, and the identiWcation of patients with particular molecular targets likely to respond to speciWc drugs.
